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Abstract
Background: We examined salivary C-reactive protein (CRP) levels in the context of tobacco smoke exposure (TSE)
in healthy youth. We hypothesized that there would be a dose-response relationship between TSE status and
salivary CRP levels.
Methods: This work is a pilot study (N = 45) for a larger investigation in which we aim to validate salivary CRP
against serum CRP, the gold standard measurement of low-grade inflammation. Participants were healthy youth
with no self-reported periodontal disease, no objectively measured obesity/adiposity, and no clinical depression,
based on the Beck Depression Inventory (BDI-II). We assessed tobacco smoking and confirmed smoking status
(non-smoking, passive smoking, and active smoking) with salivary cotinine measurement. We measured salivary
CRP by the ELISA method. We controlled for several potential confounders.
Results: We found evidence for the existence of a dose-response relationship between the TSE status and salivary
CRP levels.
Conclusions: Our preliminary findings indicate that salivary CRP seems to have a similar relation to TSE as its
widely used serum (systemic inflammatory) biomarker counterpart.
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Background
T h ep r o v i n c eo fN e wB r u n s w i c k( N B ) ,w h e r et h i sp i l o t
study took place, has one of the highest smoking rates
in Canada at 18.1% (with 19.9% of males and 16.5% of
females smoking daily) [1]. Undergraduate years are a
time of stress and exploration. Consequently, many
youth develop permanent smoking habits, and about
one-third of them will become addicted to cigarette
smoking [2]. Both active and passive tobacco smoke
exposure (TSE) are related to an increased risk of cardi-
ovascular events and diseases [3,4], by altering the auto-
nomic function or by inducing pro-inflammatory
responses [4-6].
Inflammation, acute and systemic, is part of our
immune reaction and leads to the release of C-reactive
protein (CRP) into the bloodstream [7-9]. However,
chronically increased serum CRP is a risk factor for the
development of coronary artery disease (CAD) [10]. For
example, chronic pro-inflammatory responses play an
important role in the induction and progression of
atherosclerosis [11]. Understanding the mechanisms
through which TSE may affect CRP levels in young
smokers is central to the prevention of early athero-
sclerosis. This is fundamental as CAD is one of the lead-
ing causes of death of Canadian adults. Furthermore,
heart disease and stroke cost the Canadian economy
more than $22.2 billion each year [10].
Serum CRP, the gold standard measurement of low-
grade inflammation, can predict future cardiac events,
even in healthy individuals [8]. Thus, serum CRP is
often utilized to assess future CAD risk. However,
serum testing is invasive in nature. In contrast, the sali-
vary CRP assay, commercially available since November
2008 (e.g., Salimetrics Europe), is minimally invasive and
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serum CRP. It is therefore ideal for use in research on
TSE in youth.
The aim of this pilot study was to investigate salivary
CRP levels in the context of TSE in healthy youth.
Based on findings with serum CRP [14], we tested the
hypothesis of a dose-response relationship between TSE
status (active, passive, non-smoking) and salivary CRP
levels. Specifically, we hypothesized that salivary CRP
levels would rise in a dose-response manner with the
extent of TSE.
Methods
Study design & participants
An a priori power analysis indicated that a minimum of
30 participants would be sufficient to achieve power of
0.80 with an a for the ANOVA set at 0.05, and with a
moderate-to-large effect size (f
2 = 0.50 to 0.80). To pre-
vent or account for possible attrition/missing data, we
recruited 45 healthy youth. The inclusion criterion was
to be a first year university student enrolled in an
“Introductory Psychology” course. Table 1 shows our
exclusion criteria to determine the eligibility of inter-
ested participants. We collected demographic and health
data to screen for exclusion criteria, and/or to control
for potential confounders. Sixty students were
approached and screened, from which 45 eligible partici-
pants (28 females and 17 males) were enrolled in the
study. Their mean age was 18.89 years (SD = 2.62). The
study was approved by the institution’s Research Ethics
Board. Written informed consent was obtained from the
participants of this study.
Materials
TSE status
W eu s e dt h eT o b a c c oU s eQ u e s t i o n n a i r e( T U Q ) ,
adapted from O’Loughlin et al. [14], which exhibited
good reliability and validity with a Canadian youth
population. The items were selected from a set of ques-
tions pertaining to smoking history that were used in
the Québec Child and Adolescent Health Social Survey
(QCAHSS); the latter were extracted from the 1994
Canadian Survey of Smoking among youths [14]. The
TUQ asks about rate of smoking, type of tobacco pro-
ducts used, and if participants are/were exposed to
tobacco smoke in their past or current living environ-
ments. We used the TUQ to identify non-smokers, pas-
sive smokers, and smokers (≥ 1 cigarette/day, on a daily
basis). We confirmed TSE status with salivary cotinine
measurement (Salimetrics, State College, PA, USA). The
intra-assay coefficient of variation (CV) of the cotinine
assay was 6.5%. The inter-assay CV was 4.21% for low
values and 9.04% for high values. Cotinine high sensitiv-
ity enzyme immunoassays (EIA) were performed in
duplicate. The repeated EIAs were highly correlated (r =
.99, p < 0.001). Smokers had significantly higher cotinine
levels (M=97.34, SD = 138.80) than passive smokers
(M =0 . 6 9 ,SD = 0.96), t(12) = 3.15, p = 0.009. Smokers
also had higher cotinine levels than non-smokers (M =
.83, SD =1 . 1 1 ) ,t(12) = 3.15, p = 0.009. However, coti-
nine levels were not significantly different between pas-
sive smokers and non-smokers (p > 0.05).
Salivary CRP levels
Salivary CRP is the main and single outcome measure of
this study. Although salivary CRP does not appear to be
flow rate dependent [13], flow saliva rate was deter-
mined while collecting the samples. In order to avoid
any possible fluctuations in CRP levels, we tested female
participants between the 4
th and 10
th day of the men-
strual cycle. The saliva samples were immediately stored
at -20°C until analysis (to avoid bacterial growth and
loss of CRP). The concentrations of salivary CRP levels
were measured by the ELISA method (Salimetrics, LLC,
Pennsylvania, USA). For optimal quality-control, the
same technician analyzed all samples. The % of cross-
reactivity was < 0.004 for several compounds, including
human albumin, IL-6, lysozyme, and alpha 1-Antitryp-
sin. The intra-assay CV of the CRP assay was 1.9% and
the inter-assay CV was 3.7%. CRP assays were run in
duplicates. Again, the repeated measures were highly
correlated, r > .99, p < .001.
Table 1 Exclusion Criteria for Participants
Criteria Rationale
Periodontal disease
(self-reported).
There is a positive relationship between salivary CRP and periodontal
disease, which could help to explain the underlying link between
periodontal disease and higher risk for CAD [27].
Obesity
(based on body mass index measurement).
Obesity is a major determinant of elevated serum CRP [28].
Apparent clinical levels of depressive symptoms
(screened with the Beck Depression Inventory-2
nd edition, BDI-II [24],
which has been validated specifically with university students [25,26]).
There is increasing evidence of a relationship between depressive
symptoms and elevated serum CRP, putting individuals at increased cardiac
risk [8]. Depression has also been shown to be related to TSE [29].
The BDI-II is a standard measure of depression used in research that is highly correlated with the presence of symptoms of depression. The BDI-II clinical cut-off
is used to indicate a high likelihood of a depressive clinical disorder.
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Based on the available literature on systemic inflamma-
tion [8,15,16], we specified a priori the following poten-
tial covariates: cold/flu or infection within the past 2
weeks, systemic diseases such as diabetes mellitus, medi-
cation use such as statins, aspirin, contraceptive pills,
age, body mass index (measured in kg/m
2), non-clinical
levels of depressive symptoms (BDI-II), and other sub-
stance use. The substance use was determined from the
Simple Screening Instrument for Substance Abuse (SSI-
SA), which is appropriate for use with youth [17]. Simi-
larly, we established the following a priori potential cov-
ariates for cotinine measurement: intake of tea,
tomatoes, potatoes and eggplants as these contain small
amounts of nicotine that may contribute to the salivary
cotinine levels [18]. To test our hypothesis, we com-
pared differences in salivary CRP levels of non-smoking,
passive smoking, and active smoking groups using an
ANOVA and post-hoc t-tests.
Results
Ten youth (22.2%) were active smokers, 22 were passive
smokers (48.9%), and 13 youth (28.9%) were never smo-
kers. The average number of daily smoked cigarettes
w a s4 . 7 8( S D=6 . 1 6 ) .W ee x a m i n e ds a l i v a r yC R Pl e v e l s
in healthy youth, as a function of TSE levels. None of
the potential confounders mentioned above was signifi-
cantly correlated with CRP levels. Thus, we have not
included them as covariates in the analyses. With an
A N O V Af o l l o w e db yp o s t - h o ct - t e s t s ,w ec o m p a r e d
differences in CRP levels of three groups: active smokers
(smoking ≥ 1 cigarette, on a daily basis), passive smo-
kers, and non-smokers. We found evidence for the exis-
tence of a dose-response relationship between the TSE
status and salivary CRP levels (N = 45) (see Figure 1).
There were significant differences between groups (F (2,
39) = 5.39, p =0 . 0 1 ,h
2 = .22). Specifically, active smo-
kers had significantly higher CRP levels (M = 2780.10
ng/ml, SD = 2501.76) than non-smokers (M = 371.63
ng/ml, SD = 255.22) (t (14) = 3.57, p =0 . 0 0 ) .P a s s i v e
smokers (M = 1826.54 ng/ml, SD = 2744.30) also had
significantly higher CRP levels than non-smokers (t (30)
= 2.73, p = 0.011). Interestingly, the difference between
the CRP levels of passive smokers and active smokers
did not reach significance (t (32) = 1.24, p =0 . 2 2 ) .I n
addition, although salivary CRP levels were positively
correlated with smoking status (r (40) = .45, p = 0.003).
CRP and cotinine concentrations were not significantly
correlated with each other (p > 0.05).
Discussion
This pilot study explored the immunomodulatory effects
of TSE among healthy youth,a si n d e x e db ys a l i v a r y
CRP. CRP levels were highest in active smokers, lower
in passive smokers, and lowest in non-smokers. This
supported our hypothesis of a “dose-response” effect of
TSE on salivary CRP levels. This finding corroborated
results of studies using the more widely used serum
CRP measure [5,9,14,19]. Thus our preliminary findings
suggests that salivary CRP seems to have a similar
Figure 1 Mean log salivary CRP (in ng/ml) for TSE status groups. P values for comparisons with mean log salivary CRP of the non-smokers
were 0.01 and 0.003 for the passive and active smoking groups respectively. Error bars indicate standard deviation.
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inflammatory) biomarker counterpart [20].
A recent study [21] investigated salivary and serum CRP
in healthy medical students. Although not focusing on
smoking, high correlations between the two CRP biomar-
kers were not found. However, the study was limited by: 1.
the absence of age-related reference ranges for the salivary
CRP test and 2. a lack of control for periodontal disease.
The latter is significant as elevated salivary CRP levels
have been shown to indicate poor periodontal health or
chronic oral infections (related to tissues/structures sup-
porting the teeth). In addition, oral chronic infections have
been linked to CAD [4]. More precisely, this link might be
partly explained by systemic chronic inflammation [4,21],
possibly in the form of subtle persistent low-grade inflam-
mation originating from oral chronic infections.
Our study is among the very scarce literature on CRP
in human saliva. To the best of our knowledge, this is
the first investigation examining salivary CRP levels as a
function of TSE levels. The strengths of this pilot study
include taking into account several potential confoun-
ders. Most importantly, we ruled out the effects of
reported periodontal diseaseo nt h ef i n d i n g s( e x c l u s i o n
criterion). Ideally, assessing plaque induced gingivitis,
while recording more objective indices of periodontal
health, would have been a more precise measure of oral
health. Although we have used a high-sensitivity salivary
EIA assay, it is possible that this assay was not sensitive
enough to capture any difference in cotinine levels
between passive smokers and non-smokers. Further-
more, self-reports of undesirable social behaviours, like
s m o k i n g ,m a yb ep r o n et ou n d e r - r e p o r t i n gi ns o m e
populations (e.g., ill older adults, pregnant women).
Although under-reporting is insignificant in healthy
youth, potential misclassification of smokers due to self-
reporting remains a possibility. This limitation is miti-
gated by the use of cotinine testing. Cotinine, which is a
specific, sensitive valid biomarker for determining expo-
sure to “tobacco/nicotine”, confirmed the integrity of
the self-reported smoking data. Finally, different levels
of physical activity, between participants in the TSE
groups (active, passive), might have influenced our
results. As the pilot testing did not measure physical
activity, this remains a possibility that deserves future
investigation [22].
Conclusion
Inflammation may be an important physiological
mechanism by which tobacco use increases risk for
atherosclerosis and eventually CAD [23]. Thus, a practi-
cal use of our finding of dose-response relationship
between TSE status and salivary CRP in young healthy
smokers would be to: 1) Provide more evidence to the
importance of the inflammatory pathway underlying
cardiovascular risky behaviours in healthy youth and 2)
Perhaps more importantly, suggest promising evidence
that a simple, less invasive, & non-painful biomarker
might be an alternative to the more invasive serum mea-
sure of CRP.
Our pilot finding is encouraging as it has the potential
to support the future application of salivary CRP assays
in populational research, and possibly eventually in clini-
cal settings (at least in the context of young populations
exposed to tobacco smoke). Further research should
examine the relationship between changes in salivary
CRP with serum CRP and investigate the stability of the
salivary CRP biomarker over extended periods of time.
These are the next steps to our pilot study. Once these
steps are completed, we could assess whether the sali-
vary CRP test has the potential to be a non-invasive and
practical clinical tool to monitor risk for cardiovascular
diseases in large populations.
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